Quince Therapeutics, Inc. (QNCX) 10-Year Financial Performance & Capital Metrics

QNCX • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutQuince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.Show more

Revenue $0
EBITDA -$57M -66.5%
Net Income -$57M -81.1%
EPS (Diluted) -1.31 -56.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -98.63% -191.8%
ROIC -73.51% -90.6%
Debt/Equity 0.49 +202.6%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 94 (top 6%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Shares diluted 16.2% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-6.97%

EPS CAGR

10Y-

5Y-

3Y-

TTM3.2%

ROCE

10Y Avg-59.78%

5Y Avg-46.17%

3Y Avg-38.02%

Latest-41.24%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-
Cost of Goods Sold+	45K	51K	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	-45K	-51K	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-0.13%	1%	-	-	-	-	-
Operating Expenses+	10.37M	12.12M	39.17M	78.89M	90.32M	52.02M	34.62M	57.28M
OpEx % of Revenue	-	-	-	-	-	-	-	-
Selling, General & Admin	1.27M	2.03M	8.95M	17.59M	29.52M	26.01M	17.7M	17.58M
SG&A % of Revenue	-	-	-	-	-	-	-	-
Research & Development	9.1M	10.09M	30.21M	61.31M	60.8M	25.18M	9.45M	18.59M
R&D % of Revenue	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	825K	7.48M	21.11M
Operating Income+	-10.37M	-12.12M	-39.17M	-78.89M	-90.32M	-52.02M	-34.62M	-57.28M
Operating Margin %	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-0.17%	-2.23%	-1.01%	-0.14%	0.42%	0.33%	-0.65%
EBITDA+	-10.32M	-12.07M	-38.98M	-78.56M	-89.97M	-51.81M	-34.3M	-57.1M
EBITDA Margin %	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-0.17%	-2.23%	-1.02%	-0.15%	0.42%	0.34%	-0.66%
D&A (Non-Cash Add-back)	45K	51K	188K	332K	344K	204K	322K	186K
EBIT	-10.37M	-11.52M	-39.17M	-78.89M	-90.32M	-51.19M	-27.14M	-36.17M
Net Interest Income+	0	-151K	2.19M	2.04M	620K	500K	3.48M	2.93M
Interest Income	0	806K	2.19M	2.04M	620K	1.07M	3.48M	2.93M
Interest Expense	1.64M	957K	0	0	0	568K	0	0
Other Income/Expense	-1.86M	-357K	2.19M	2.04M	373K	71K	3.04M	544K
Pretax Income+	-12.23M	-12.48M	-36.98M	-76.85M	-89.94M	-51.94M	-31.58M	-56.74M
Pretax Margin %	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	-284K	-197K	87K
Effective Tax Rate %	1%	1%	1%	1%	1%	0.99%	0.99%	1%
Net Income+	-12.23M	-12.48M	-36.98M	-76.85M	-89.94M	-51.66M	-31.39M	-56.83M
Net Margin %	-	-	-	-	-	-	-	-
Net Income Growth %	-	-0.02%	-1.96%	-1.08%	-0.17%	0.43%	0.39%	-0.81%
Net Income (Continuing)	-12.23M	-12.48M	-36.98M	-76.85M	-89.94M	-51.66M	-31.39M	-56.83M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.57	-0.58	-1.93	-2.63	-3.03	-1.54	-0.84	-1.31
EPS Growth %	-	-0.02%	-2.33%	-0.36%	-0.15%	0.49%	0.45%	-0.56%
EPS (Basic)	-0.57	-0.58	-1.93	-2.63	-3.03	-1.54	-0.84	-1.31
Diluted Shares Outstanding	21.55M	21.55M	19.03M	29.18M	29.72M	33.5M	37.24M	43.26M
Basic Shares Outstanding	21.55M	21.55M	19.03M	29.18M	29.72M	33.5M	37.24M	43.26M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	7.54M	72.58M	106.06M	137.86M	111.67M	93.75M	77.44M	44.04M
Cash & Short-Term Investments	7.34M	71.72M	99.86M	133.82M	106.8M	90.18M	75.06M	40.78M
Cash Only	7.34M	24.87M	51.21M	66.84M	69.72M	44.58M	20.75M	6.21M
Short-Term Investments	0	46.84M	48.65M	66.98M	37.08M	45.6M	54.31M	34.57M
Accounts Receivable	0	0	0	0	1.13M	0	993K	882K
Days Sales Outstanding	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	143K	821K	688K	694K	367K	2.37M	81K	84K
Total Non-Current Assets+	181K	293K	18.31M	51.6M	21.55M	10.16M	102.76M	70.44M
Property, Plant & Equipment	122K	283K	1.33M	1.1M	1.43M	684K	619K	813K
Fixed Asset Turnover	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	17.63M	0
Intangible Assets	0	0	0	0	0	5.9M	63.67M	60.05M
Long-Term Investments	0	0	16.76M	50.46M	19.93M	3.58M	78K	78K
Other Non-Current Assets	59K	10K	217K	39K	194K	3.58M	8.47M	9.51M
Total Assets+	7.72M	72.88M	124.37M	189.47M	133.23M	103.91M	180.2M	114.48M
Asset Turnover	-	-	-	-	-	-	-	-
Asset Growth %	-	8.44%	0.71%	0.52%	-0.3%	-0.22%	0.73%	-0.36%
Total Current Liabilities+	1.76M	1.46M	8.89M	17M	14.22M	3.07M	9.57M	7.28M
Accounts Payable	517K	495K	3.08M	3.56M	4.91M	570K	2.03M	2.9M
Days Payables Outstanding	4.19K	3.54K	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	64K	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	10.79M	180K	916K	5.13M	308K
Current Ratio	4.28x	49.82x	11.93x	8.11x	7.85x	30.55x	8.09x	6.05x
Quick Ratio	4.28x	49.82x	11.93x	8.11x	7.85x	30.55x	8.09x	6.05x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	26.23M	495K	3.08M	208K	420K	248K	85.55M	77.05M
Long-Term Debt	7.17M	0	0	0	0	0	13.43M	14.32M
Capital Lease Obligations	0	0	0	208K	420K	0	321K	394K
Deferred Tax Liabilities	0	0	0	0	0	248K	17.61M	4.96M
Other Non-Current Liabilities	19.06M	0	0	0	0	0	54.19M	57.38M
Total Liabilities	28M	1.46M	8.89M	17.2M	14.64M	3.32M	95.12M	84.33M
Total Debt+	7.17M	0	0	446K	1.16M	453K	13.81M	14.81M
Net Debt	-172K	-24.87M	-51.21M	-66.39M	-68.56M	-44.13M	-6.94M	8.6M
Debt / Equity	-	-	-	0.00x	0.01x	0.00x	0.16x	0.49x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-6.31x	-12.66x	-	-	-	-91.58x	-	-
Total Equity+	-20.28M	71.42M	115.48M	172.26M	118.59M	100.59M	85.08M	30.15M
Equity Growth %	-	4.52%	0.62%	0.49%	-0.31%	-0.15%	-0.15%	-0.65%
Book Value per Share	-0.94	3.31	6.07	5.90	3.99	3.00	2.28	0.70
Total Shareholders' Equity	-20.28M	71.42M	115.48M	172.26M	118.59M	100.59M	85.08M	30.15M
Common Stock	3K	22K	27K	29K	30K	36K	43K	44K
Retained Earnings	-20.35M	-32.83M	-69.81M	-146.65M	-236.6M	-288.26M	-319.64M	-376.47M
Treasury Stock	0	-220K	0	0	0	0	0	0
Accumulated OCI	-17.18M	-49K	60K	313K	-79K	-289K	3.05M	-35K
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-9.83M	-11.7M	-33.28M	-50.82M	-62.93M	-44.04M	-18.29M	-31.9M
Operating CF Margin %	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-0.19%	-1.85%	-0.53%	-0.24%	0.3%	0.58%	-0.74%
Net Income	-12.23M	-12.48M	-36.98M	-76.85M	-89.94M	-51.66M	-31.39M	-56.83M
Depreciation & Amortization	45K	51K	188K	332K	344K	204K	322K	186K
Stock-Based Compensation	38K	155K	2.06M	14.47M	29.85M	16.62M	5.22M	4.75M
Deferred Taxes	222K	-145K	-812K	635K	878K	-284K	-248K	0
Other Non-Cash Items	1.64M	1.11M	367K	367K	199K	913K	5.82M	20.48M
Working Capital Changes	460K	-390K	1.9M	10.23M	-4.26M	-9.83M	1.98M	-484K
Change in Receivables	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	223K	-23K	2.58M	480K	1.36M	-5.94M	-288K	927K
Cash from Investing+	-77K	-46.75M	-17.75M	-52.43M	58.95M	18M	-5.76M	21.91M
Capital Expenditures	-77K	-212K	-55K	-52K	-180K	-133K	-160K	-257K
CapEx % of Revenue	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	-46.54M	812K	-52.43M	58.95M	70K	-910K	2.35M
Cash from Financing+	7.75M	75.93M	77.37M	118.88M	6.81M	707K	143K	-4.78M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	0	-10K	98K	1.28M	0	148K	0	-5M
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-9.9M	-11.91M	-33.33M	-50.87M	-63.11M	-44.17M	-18.45M	-32.16M
FCF Margin %	-	-	-	-	-	-	-	-
FCF Growth %	-	-0.2%	-1.8%	-0.53%	-0.24%	0.3%	0.58%	-0.74%
FCF per Share	-0.46	-0.55	-1.75	-1.74	-2.12	-1.32	-0.50	-0.74
FCF Conversion (FCF/Net Income)	0.80x	0.94x	0.90x	0.66x	0.70x	0.85x	0.58x	0.56x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	1K	1K	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-48.79%	-39.57%	-53.42%	-61.85%	-47.14%	-33.81%	-98.63%
Return on Invested Capital (ROIC)	-	-69.66%	-53.02%	-69.56%	-86.91%	-73.27%	-38.58%	-73.51%
Debt / Equity	-	-	-	0.00x	0.01x	0.00x	0.16x	0.49x
Interest Coverage	-6.31x	-12.66x	-	-	-	-91.58x	-	-
FCF Conversion	0.80x	0.94x	0.90x	0.66x	0.70x	0.85x	0.58x	0.56x

Frequently Asked Questions

Growth & Financials

Quince Therapeutics, Inc. (QNCX) grew revenue by 0.0% over the past year. Growth has been modest.

Quince Therapeutics, Inc. (QNCX) reported a net loss of $57.0M for fiscal year 2024.

Dividend & Returns

Quince Therapeutics, Inc. (QNCX) has a return on equity (ROE) of -98.6%. Negative ROE indicates the company is unprofitable.

Quince Therapeutics, Inc. (QNCX) had negative free cash flow of $39.0M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

Quince Therapeutics, Inc. (QNCX) 10-Year Financial Performance & Capital Metrics

QNCX • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $0
EBITDA -$57M -66.5%
Net Income -$57M -81.1%
EPS (Diluted) -1.31 -56.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -98.63% -191.8%
ROIC -73.51% -90.6%
Debt/Equity 0.49 +202.6%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 94 (top 6%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Shares diluted 16.2% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-6.97%

EPS CAGR

10Y-

5Y-

3Y-

TTM3.2%

ROCE

10Y Avg-59.78%

5Y Avg-46.17%

3Y Avg-38.02%

Latest-41.24%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-
Cost of Goods Sold+	45K	51K	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	-45K	-51K	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-0.13%	1%	-	-	-	-	-
Operating Expenses+	10.37M	12.12M	39.17M	78.89M	90.32M	52.02M	34.62M	57.28M
OpEx % of Revenue	-	-	-	-	-	-	-	-
Selling, General & Admin	1.27M	2.03M	8.95M	17.59M	29.52M	26.01M	17.7M	17.58M
SG&A % of Revenue	-	-	-	-	-	-	-	-
Research & Development	9.1M	10.09M	30.21M	61.31M	60.8M	25.18M	9.45M	18.59M
R&D % of Revenue	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	825K	7.48M	21.11M
Operating Income+	-10.37M	-12.12M	-39.17M	-78.89M	-90.32M	-52.02M	-34.62M	-57.28M
Operating Margin %	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-0.17%	-2.23%	-1.01%	-0.14%	0.42%	0.33%	-0.65%
EBITDA+	-10.32M	-12.07M	-38.98M	-78.56M	-89.97M	-51.81M	-34.3M	-57.1M
EBITDA Margin %	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-0.17%	-2.23%	-1.02%	-0.15%	0.42%	0.34%	-0.66%
D&A (Non-Cash Add-back)	45K	51K	188K	332K	344K	204K	322K	186K
EBIT	-10.37M	-11.52M	-39.17M	-78.89M	-90.32M	-51.19M	-27.14M	-36.17M
Net Interest Income+	0	-151K	2.19M	2.04M	620K	500K	3.48M	2.93M
Interest Income	0	806K	2.19M	2.04M	620K	1.07M	3.48M	2.93M
Interest Expense	1.64M	957K	0	0	0	568K	0	0
Other Income/Expense	-1.86M	-357K	2.19M	2.04M	373K	71K	3.04M	544K
Pretax Income+	-12.23M	-12.48M	-36.98M	-76.85M	-89.94M	-51.94M	-31.58M	-56.74M
Pretax Margin %	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	-284K	-197K	87K
Effective Tax Rate %	1%	1%	1%	1%	1%	0.99%	0.99%	1%
Net Income+	-12.23M	-12.48M	-36.98M	-76.85M	-89.94M	-51.66M	-31.39M	-56.83M
Net Margin %	-	-	-	-	-	-	-	-
Net Income Growth %	-	-0.02%	-1.96%	-1.08%	-0.17%	0.43%	0.39%	-0.81%
Net Income (Continuing)	-12.23M	-12.48M	-36.98M	-76.85M	-89.94M	-51.66M	-31.39M	-56.83M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.57	-0.58	-1.93	-2.63	-3.03	-1.54	-0.84	-1.31
EPS Growth %	-	-0.02%	-2.33%	-0.36%	-0.15%	0.49%	0.45%	-0.56%
EPS (Basic)	-0.57	-0.58	-1.93	-2.63	-3.03	-1.54	-0.84	-1.31
Diluted Shares Outstanding	21.55M	21.55M	19.03M	29.18M	29.72M	33.5M	37.24M	43.26M
Basic Shares Outstanding	21.55M	21.55M	19.03M	29.18M	29.72M	33.5M	37.24M	43.26M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	7.54M	72.58M	106.06M	137.86M	111.67M	93.75M	77.44M	44.04M
Cash & Short-Term Investments	7.34M	71.72M	99.86M	133.82M	106.8M	90.18M	75.06M	40.78M
Cash Only	7.34M	24.87M	51.21M	66.84M	69.72M	44.58M	20.75M	6.21M
Short-Term Investments	0	46.84M	48.65M	66.98M	37.08M	45.6M	54.31M	34.57M
Accounts Receivable	0	0	0	0	1.13M	0	993K	882K
Days Sales Outstanding	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	143K	821K	688K	694K	367K	2.37M	81K	84K
Total Non-Current Assets+	181K	293K	18.31M	51.6M	21.55M	10.16M	102.76M	70.44M
Property, Plant & Equipment	122K	283K	1.33M	1.1M	1.43M	684K	619K	813K
Fixed Asset Turnover	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	17.63M	0
Intangible Assets	0	0	0	0	0	5.9M	63.67M	60.05M
Long-Term Investments	0	0	16.76M	50.46M	19.93M	3.58M	78K	78K
Other Non-Current Assets	59K	10K	217K	39K	194K	3.58M	8.47M	9.51M
Total Assets+	7.72M	72.88M	124.37M	189.47M	133.23M	103.91M	180.2M	114.48M
Asset Turnover	-	-	-	-	-	-	-	-
Asset Growth %	-	8.44%	0.71%	0.52%	-0.3%	-0.22%	0.73%	-0.36%
Total Current Liabilities+	1.76M	1.46M	8.89M	17M	14.22M	3.07M	9.57M	7.28M
Accounts Payable	517K	495K	3.08M	3.56M	4.91M	570K	2.03M	2.9M
Days Payables Outstanding	4.19K	3.54K	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	64K	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	10.79M	180K	916K	5.13M	308K
Current Ratio	4.28x	49.82x	11.93x	8.11x	7.85x	30.55x	8.09x	6.05x
Quick Ratio	4.28x	49.82x	11.93x	8.11x	7.85x	30.55x	8.09x	6.05x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	26.23M	495K	3.08M	208K	420K	248K	85.55M	77.05M
Long-Term Debt	7.17M	0	0	0	0	0	13.43M	14.32M
Capital Lease Obligations	0	0	0	208K	420K	0	321K	394K
Deferred Tax Liabilities	0	0	0	0	0	248K	17.61M	4.96M
Other Non-Current Liabilities	19.06M	0	0	0	0	0	54.19M	57.38M
Total Liabilities	28M	1.46M	8.89M	17.2M	14.64M	3.32M	95.12M	84.33M
Total Debt+	7.17M	0	0	446K	1.16M	453K	13.81M	14.81M
Net Debt	-172K	-24.87M	-51.21M	-66.39M	-68.56M	-44.13M	-6.94M	8.6M
Debt / Equity	-	-	-	0.00x	0.01x	0.00x	0.16x	0.49x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-6.31x	-12.66x	-	-	-	-91.58x	-	-
Total Equity+	-20.28M	71.42M	115.48M	172.26M	118.59M	100.59M	85.08M	30.15M
Equity Growth %	-	4.52%	0.62%	0.49%	-0.31%	-0.15%	-0.15%	-0.65%
Book Value per Share	-0.94	3.31	6.07	5.90	3.99	3.00	2.28	0.70
Total Shareholders' Equity	-20.28M	71.42M	115.48M	172.26M	118.59M	100.59M	85.08M	30.15M
Common Stock	3K	22K	27K	29K	30K	36K	43K	44K
Retained Earnings	-20.35M	-32.83M	-69.81M	-146.65M	-236.6M	-288.26M	-319.64M	-376.47M
Treasury Stock	0	-220K	0	0	0	0	0	0
Accumulated OCI	-17.18M	-49K	60K	313K	-79K	-289K	3.05M	-35K
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-9.83M	-11.7M	-33.28M	-50.82M	-62.93M	-44.04M	-18.29M	-31.9M
Operating CF Margin %	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-0.19%	-1.85%	-0.53%	-0.24%	0.3%	0.58%	-0.74%
Net Income	-12.23M	-12.48M	-36.98M	-76.85M	-89.94M	-51.66M	-31.39M	-56.83M
Depreciation & Amortization	45K	51K	188K	332K	344K	204K	322K	186K
Stock-Based Compensation	38K	155K	2.06M	14.47M	29.85M	16.62M	5.22M	4.75M
Deferred Taxes	222K	-145K	-812K	635K	878K	-284K	-248K	0
Other Non-Cash Items	1.64M	1.11M	367K	367K	199K	913K	5.82M	20.48M
Working Capital Changes	460K	-390K	1.9M	10.23M	-4.26M	-9.83M	1.98M	-484K
Change in Receivables	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	223K	-23K	2.58M	480K	1.36M	-5.94M	-288K	927K
Cash from Investing+	-77K	-46.75M	-17.75M	-52.43M	58.95M	18M	-5.76M	21.91M
Capital Expenditures	-77K	-212K	-55K	-52K	-180K	-133K	-160K	-257K
CapEx % of Revenue	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	-46.54M	812K	-52.43M	58.95M	70K	-910K	2.35M
Cash from Financing+	7.75M	75.93M	77.37M	118.88M	6.81M	707K	143K	-4.78M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	0	-10K	98K	1.28M	0	148K	0	-5M
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-9.9M	-11.91M	-33.33M	-50.87M	-63.11M	-44.17M	-18.45M	-32.16M
FCF Margin %	-	-	-	-	-	-	-	-
FCF Growth %	-	-0.2%	-1.8%	-0.53%	-0.24%	0.3%	0.58%	-0.74%
FCF per Share	-0.46	-0.55	-1.75	-1.74	-2.12	-1.32	-0.50	-0.74
FCF Conversion (FCF/Net Income)	0.80x	0.94x	0.90x	0.66x	0.70x	0.85x	0.58x	0.56x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	1K	1K	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-48.79%	-39.57%	-53.42%	-61.85%	-47.14%	-33.81%	-98.63%
Return on Invested Capital (ROIC)	-	-69.66%	-53.02%	-69.56%	-86.91%	-73.27%	-38.58%	-73.51%
Debt / Equity	-	-	-	0.00x	0.01x	0.00x	0.16x	0.49x
Interest Coverage	-6.31x	-12.66x	-	-	-	-91.58x	-	-
FCF Conversion	0.80x	0.94x	0.90x	0.66x	0.70x	0.85x	0.58x	0.56x

Frequently Asked Questions

Growth & Financials

Quince Therapeutics, Inc. (QNCX) grew revenue by 0.0% over the past year. Growth has been modest.

Quince Therapeutics, Inc. (QNCX) reported a net loss of $57.0M for fiscal year 2024.

Dividend & Returns

Quince Therapeutics, Inc. (QNCX) has a return on equity (ROE) of -98.6%. Negative ROE indicates the company is unprofitable.

Quince Therapeutics, Inc. (QNCX) had negative free cash flow of $39.0M in fiscal year 2024, likely due to heavy capital investments.